Clinical-stage biopharmaceutical company vTv Therapeutics has started a Phase II trial of TTP273 to treat type-2 diabetes.

Type 2 diabetes is a chronic syndrome caused due to dysregulation of blood sugar levels. It is the most common type of diabetes representing 90%-95% of diabetes patients.

The Phase II aLlosteric Oral Glp1 Receptor Agonist (LOGRA) study will evaluate the safety and efficacy of TTP273 in type 2 diabetic patients on stable doses of metformin.

The company has started enrolling patients in the LOGRA trial to assess TTP273, which is an oral, small molecule GLP-1R agonist.

"TTP273 has the potential to provide enhanced glycemic control and weight loss without the burden of injections."

Around 156 patients will be enroled at 26 clinical trial sites throughout the US.

The study’s primary endpoint is change in baseline in HbA1c at three months, with secondary endpoints including body weight, plasma glucose, lipids insulin, lactate, C-peptide, glucagon and GLP.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

vTv Therapeutics president and CEO Steve Holcombe said: "Earlier studies of this compound showed that TTP273 has the potential to provide enhanced glycemic control and weight loss without the burden of injections or gastrointestinal side effects seen with GLP-1 biologic agents.

"TTP273 is just one of two diabetes treatments in our pipeline reading out this year with our best-in-class orally administered Glucokinase Activator, TTP399, expected to report Phase 2 results in mid-2016."

The Phase 1b trial of TTP273 showed efficacy for postprandial and fasting glucose. All doses of TTP273 were found to be safe and well tolerated with no serious adverse events or evidence of gastrointestinal side effects.